ArticlePloS one2015
Immunologic and Virologic Progression in HIV Controllers: The Role of Viral "Blips" and Immune Activation in the ANRS CO21 CODEX Study.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 53 citations in OpenAlex.
- Major Depressive Episodes and Psychiatric Symptoms Among HIV Controllers Compared With Antiretroviral-Treated People Living With HIV.Open forum infectious diseases · 2026Article
- The elite controller phenotype.Current opinion in HIV and AIDS · 2026Review
- Longitudinal plasma proteomic signatures of elite and viremic spontaneous HIV controllers.Nature communications · 2026Article
- In-Depth Characterization of Full-Length Archived Viral Genomes after Nine Years of Posttreatment HIV Control.Microbiology spectrum · 2023Article
- Slow progression of pediatric HIV associates with early CD8+ T cell PD-1 expression and a stem-like phenotype.JCI insight · 2023Article
- Non-AIDS-Defining Events in Human Immunodeficiency Virus Controllers Versus Antiretroviral Therapy-Controlled Patients: A Cohort Collaboration From the French National Agency for Research on AIDS CO21 (CODEX) and CO06 (PRIMO) Cohorts.Open forum infectious diseases · 2023Article
- Elite controllers long-term non progressors present improved survival and slower disease progression.Scientific reports · 2022Article
- Mechanism of Viral Suppression among HIV Elite Controllers and Long-Term Nonprogressors in Nigeria and South Africa.Viruses · 2022Review
- Article
- Viral and Cellular Factors Leading to the Loss of CD4 Homeostasis in HIV-1 Viremic Nonprogressors.Journal of virology · 2022Article
- Approach to the management of paediatric HIV spontaneous controllers.Southern African journal of infectious diseases · 2022Article
- Functional impairment of HIV-specific CD8Immunity · 2021Article
- Abrupt and altered cell-type specific DNA methylation profiles in blood during acute HIV infection persists despite prompt initiation of ART.PLoS pathogens · 2021Article
- Functional Cure of Hepatitis B Virus Infection in Individuals With HIV-Coinfection: A Literature Review.Viruses · 2021Review
- Antiretroviral therapy for HIV controllers: Reasons for initiation and outcomes in the French ANRS-CO21 CODEX cohort.EClinicalMedicine · 2021Article
- High rates of long-term progression in HIV-1-positive elite controllers.Journal of the International AIDS Society · 2021Article
- Evolution of Serum Acute-Phase Glycoproteins Assessed byFrontiers in immunology · 2021Article
- Review
- Persistent HIV-controllers are more prone to spontaneously clear HCV: a retrospective cohort study.Journal of the International AIDS Society · 2020Article
- HIV-1 elite controllers: an immunovirological review and clinical perspectives.Journal of virus eradication · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Some HIV controllers (HICs) experience CD4+T cell count loss and/or lose their ability to control HIV. In this study, we investigated the rate of immunologic and/or virologic progression (ImmP/VirP) and its determinants in the ANRS CO21/CODEX cohort. Immunologic progression was defined as a lasting fall in CD4+T cell count below 350/mm(3) or more than 200/mm(3) with a baseline count below 600/mm(3). Virologic progression was defined as a HIV viral load (VL) above 2000 copies/mL on two consecutive determinations. Clinical characteristics, immune activation, ultrasensitive HIV VL and total HIV DNA were analyzed. Disease progression was observed in 15 of the 217 patients followed up between 2009 and 2013 (ImmP, n = 10; VirP, n = 5). Progressors had higher ultrasensitive HIV RNA levels at inclusion (i.e. 1-2 years before progression) than non-progressors. ImmP had also lower CD4+T cell nadir and CD4+T cell count at inclusion, and VirP had higher HIV DNA levels in blood. T cell activation and IP10 levels at inclusion were significantly higher in ImmP than in non-progressors. In summary, the lasting loss of CD4+T cells, residual HIV replication and basal levels of immune activation appear to be major determinants of progression in HICs. These factors should be considered for adjusting their follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.